Alto Neuroscience (NYSE:ANRO) Announces Earnings Results, Beats Estimates By $0.07 EPS

Alto Neuroscience (NYSE:ANRO) released its earnings results on Tuesday. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07, Yahoo Finance reports.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO traded up $0.53 on Wednesday, reaching $9.51. 81,718 shares of the company traded hands, compared to its average volume of 193,278. The company has a debt-to-equity ratio of 0.05, a quick ratio of 26.02 and a current ratio of 26.02. The firm has a 50 day simple moving average of $11.90. Alto Neuroscience has a fifty-two week low of $7.91 and a fifty-two week high of $24.00.

Insider Transactions at Alto Neuroscience

In other news, insider Adam Savitz acquired 12,069 shares of Alto Neuroscience stock in a transaction on Tuesday, July 9th. The stock was bought at an average cost of $12.60 per share, with a total value of $152,069.40. Following the completion of the purchase, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Wall Street Analyst Weigh In

Several analysts have commented on the company. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Wednesday, June 12th. Rodman & Renshaw began coverage on shares of Alto Neuroscience in a report on Friday, June 21st. They issued a “buy” rating and a $43.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Alto Neuroscience has a consensus rating of “Buy” and a consensus target price of $35.00.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.